Longitude Capital Partners V, LLC Reports 5.7% Stake in CytomX Therapeutics, Inc.

Longitude Capital Partners V, LLC, along with several affiliated entities and individuals, filed a Schedule 13G/A on May 15, 2026, disclosing a significant ownership stake in CytomX Therapeutics, Inc. (CTMX). As of the event date of March 31, 2026, Longitude Venture Partners V, L.P. (LVPV) is the record owner of 12,458,461 shares, representing a 5.7% stake. Additionally, Longitude 103.8 East, L.P. holds 2,830,000 shares (1.3%). Collectively, the reporting individuals, Patrick G. Enright and Juliet Tammenoms Bakker, who serve as managing members of the general partners, may be deemed to beneficially own a total of 15,288,461 shares, or approximately 7.0% of the company's common stock based on 217,702,919 shares outstanding as of April 30, 2026. The filing indicates that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting persons also noted a potential group membership with Seven Fleet Advisors LLC but expressly disclaimed beneficial ownership over any shares held by that entity.